Literature DB >> 16272168

Novel retinoblastoma binding protein RBBP9 modulates sex-specific radiation responses in vivo.

Scott Cassie1, Igor Koturbash, Darryl Hudson, Mike Baker, Yaroslav Ilnytskyy, Rocio Rodriguez-Juarez, Edgar Weber, Olga Kovalchuk.   

Abstract

Retinoblastoma (RB) tumor suppressor is a key regulator of apoptosis, a central mediator of the proliferative block induced by ionizing radiation (IR) and a binding target for a variety of proteins that regulate its activity. One of the recently discovered and the least investigated of these is the novel Rb-binding protein RBBP9/BOG. We studied the effects of acute and chronic low dose radiation (LDR) exposure on the induction of RBBP9 and RB signaling pathway in vivo in mouse spleen and found that RBBP9 played a pivotal role in IR responses in vivo. We observed that chronic LDR exposure led to a significant increase of RBBP9 expression in males and a significant decrease in females. Elevated RBBP9 expression in males was paralleled by a pronounced dephosphorylation of RB and a significant drop of PCNA and cyclin A expression. On the contrary, chronic exposure in females led to decreased levels of RBBP9 and increased levels of hyperphosphorylated RB (ppRB) in spleen. Decreased levels of ppRB in spleen of chronically exposed males were correlated with strongly elevated apoptotic rates. In females, the radiation-induced increase of apoptotic index was much less pronounced. Quite surprisingly, the observed sex-specific signaling changes did not result in the sex-specificity of cellular proliferation. The molecular mechanisms and possible repercussions of the radiation-induced sex differences in cellular proliferation and apoptosis are discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272168     DOI: 10.1093/carcin/bgi261

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

Review 1.  Human retinoblastoma binding protein 9, a serine hydrolase implicated in pancreatic cancers.

Authors:  Sergey M Vorobiev; Yuanpeng Janet Huang; Jayaraman Seetharaman; Rong Xiao; Thomas B Acton; Gaetano T Montelione; Liang Tong
Journal:  Protein Pept Lett       Date:  2012-02       Impact factor: 1.890

Review 2.  Sex-specific aspects of tumor therapy.

Authors:  Kerstin Borgmann; Ekkehard Dikomey; Cordula Petersen; Petra Feyer; Ulrike Hoeller
Journal:  Radiat Environ Biophys       Date:  2009-02-26       Impact factor: 1.925

3.  Identification of Acer2 as a First Susceptibility Gene for Lithium-Induced Nephrogenic Diabetes Insipidus in Mice.

Authors:  Theun de Groot; Lena K Ebert; Birgitte Mønster Christensen; Karolina Andralojc; Lydie Cheval; Alain Doucet; Cungui Mao; Ruben Baumgarten; Benjamin E Low; Roger Sandhoff; Michael V Wiles; Peter M T Deen; Ron Korstanje
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

4.  Comparison of growth-related traits and gene expression profiles between the offspring of neomale (XX) and normal male (XY) rainbow trout.

Authors:  Andrea L Kocmarek; Moira M Ferguson; Roy G Danzmann
Journal:  Mar Biotechnol (NY)       Date:  2015-01-30       Impact factor: 3.619

5.  RBBP9: a tumor-associated serine hydrolase activity required for pancreatic neoplasia.

Authors:  David J Shields; Sherry Niessen; Eric A Murphy; Ainhoa Mielgo; Jay S Desgrosellier; Steven K M Lau; Leo A Barnes; Jacqueline Lesperance; Michael Bouvet; David Tarin; Benjamin F Cravatt; David A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

6.  Crystal structure of human retinoblastoma binding protein 9.

Authors:  Sergey M Vorobiev; Min Su; Jayaraman Seetharaman; Yuanpeng Janet Huang; Chen X Chen; Melissa Maglaqui; Haleema Janjua; Michael Proudfoot; Alexander Yakunin; Rong Xiao; Thomas B Acton; Gaetano T Montelione; Liang Tong
Journal:  Proteins       Date:  2009-02-01

7.  Altered A-to-I RNA editing in human embryogenesis.

Authors:  Ronit Shtrichman; Igal Germanguz; Rachel Mandel; Anna Ziskind; Irit Nahor; Michal Safran; Sivan Osenberg; Ofra Sherf; Gideon Rechavi; Joseph Itskovitz-Eldor
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.